Ripu D. Jindal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ripu D. Jindal has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Matcheri S. Keshavan
Beth Israel Deaconess Medical Center
1 shared publication
Latest Publications
- 1 January 2009
- Published by Springer Nature in CNS Drugs
- Vol. 23 (4) , 309-329
Insomnia in Patients with Depression
The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in...
- 1 January 2009
- Published by Springer Nature in CNS Drugs
- Vol. 23 (4) , 309-329
Insomnia in Patients with Depression
The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in...
- 1 January 2008
- Published by Springer Nature in CNS Drugs
- Vol. 22 (12) , 1047-1059
Classifying Antipsychotic Agents
Converging data from multiple lines of research provide growing understanding of the pharmacological basis of the efficacy and tolerability of antipsychotic agents. This review highlights some of the drawbacks of the current practice of classifying antipsychotic agents into first- and second-generation agents, and argues that much of what is known about an antipsychotic agent in terms of its efficacy and tolerability can be predicted from its binding affinity at different receptors. This makes a case for a new system of classification that reflects the receptor binding affinity profiles of individual antipsychotic agents. In its quest to make a compelling case, the review provides detailed explanations for the pharmacological basis of antipsychotic efficacy, antipsychotic-induced weight gain and diabetes mellitus, cognitive effects and other adverse effects.
- 1 January 2008
- Published by Springer Nature in CNS Drugs
- Vol. 22 (12) , 1047-1059
Classifying Antipsychotic Agents
Converging data from multiple lines of research provide growing understanding of the pharmacological basis of the efficacy and tolerability of antipsychotic agents. This review highlights some of the drawbacks of the current practice of classifying antipsychotic agents into first- and second-generation agents, and argues that much of what is known about an antipsychotic agent in terms of its efficacy and tolerability can be predicted from its binding affinity at different receptors. This makes a case for a new system of classification that reflects the receptor binding affinity profiles of individual antipsychotic agents. In its quest to make a compelling case, the review provides detailed explanations for the pharmacological basis of antipsychotic efficacy, antipsychotic-induced weight gain and diabetes mellitus, cognitive effects and other adverse effects.